Adamas Pharma (ADMS) Prices 12.5M Share Follow-On Offering at $4.40/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
Adamas Pharma (ADMS) Announces Launch of Follow-on Public Offering
February 24, 2021 4:09 PM ESTAdamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of... More
Adamas Pharma (ADMS) Misses Q4 EPS by 13c
February 23, 2021 4:56 PM ESTAdamas Pharma (NASDAQ: ADMS) reported Q4 EPS of ($0.64), $0.13 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $21 million versus the consensus estimate of $20.96 million.
As of December 31, 2020, Adamas had $83.4 million of cash, cash equivalents and available-for-sale securities. Subsequent to December 31, 2020,... More
